Hyloris Pharmaceuticals, a Liège, Belgium–based innovative specialty pharmaceutical company, raised €15m in funding.
Backers included Scorpiaux, Noshaq, Saffelberg Investments and Nomainvest.
Led by Stijn Van Rompay, Chief Executive Officer and Co-founder, and Stefan Yee, Chairman of Hyloris, Hyloris identifies underserved medical needs and develops new formulations of existing drugs. The company’s development strategy is focused on the US Food and Drug Administration’s 505(b)(2) regulatory pathway for pharmaceuticals where safety and efficacy of selected molecules have already been established.
Products and product candidates span three key areas: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics).
Hyloris currently has two commercial-stage products:
- Sotalol IV for the treatment of atrial fibrillation, partnered with AltaThera and
- Maxigesic® IV, a non-opioid analgesic for the treatment of pain which is co-owned with AFT Pharmaceuticals.
The company also has 12 product candidates in various stages of development in its portfolio.
The proceeds of this funding round will, among other things, enable Hyloris to further support and execute its development and commercialisation strategy, with the aim to bring improved products to the market.